News  ›  Article

Farris LLP: Vancouver's Law Firm


11 October 2017

Mackay-Dunn, Q.C. and Murray advise Arbutus on $116m strategic investment from Roivant Sciences

On October 02, 2017, Arbutus Biopharma Corporation, an industry-leading hepatitis B virus (HBV) therapeutic solutions company, entered into a share purchase agreement with Roivant Sciences Inc. for the sale of convertible preferred shares for gross proceeds of $116.4 million. Arbutus intends to use the proceeds to further develop and advance its clinical and preclinical HBV pipeline programs.

Farris partners, Hector Mackay-Dunn, Q.C. and Ron Murray advised Arbutus on the strategic investment.

For the complete press release, click here.

‹ Back